<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Canadian Advantage Memo — Structural Cost & Regulatory Advantage</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Serif+Display&family=DM+Sans:wght@300;400;500;600;700&family=JetBrains+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
  @page { size: A4; margin: 0; }
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body {
    font-family: 'DM Sans', sans-serif; color: #1a1a2e;
    background: #fff; line-height: 1.55; font-size: 12.5px;
    max-width: 900px; margin: 0 auto;
  }
  .page { padding: 48px 56px; }
  .page + .page { border-top: 2px solid #eee; }

  .header {
    display: flex; justify-content: space-between; align-items: flex-start;
    margin-bottom: 28px; padding-bottom: 16px; border-bottom: 3px solid #1a1a2e;
  }
  .header h1 { font-family: 'DM Serif Display', serif; font-size: 26px; line-height: 1.2; }
  .header .subtitle { font-size: 14px; color: #5a5a7a; }
  .header-right { text-align: right; font-size: 11px; color: #5a5a7a; line-height: 1.6; }
  .header-right .company { font-weight: 700; color: #1a1a2e; font-size: 13px; }

  .badge {
    display: inline-block; font-size: 10px; font-weight: 600; letter-spacing: 0.08em;
    text-transform: uppercase; padding: 4px 10px; border-radius: 3px; margin-bottom: 16px;
  }
  .badge.fx { background: #dbeafe; color: #1e40af; }
  .badge.sred { background: #d1fae5; color: #065f46; }
  .badge.reg { background: #ede9fe; color: #5b21b6; }

  h2 {
    font-family: 'DM Serif Display', serif; font-size: 18px; color: #1a1a2e;
    margin: 24px 0 10px; padding-bottom: 5px; border-bottom: 1px solid #e0e0e8;
  }
  h2:first-of-type { margin-top: 0; }
  h3 {
    font-size: 11px; font-weight: 700; text-transform: uppercase;
    letter-spacing: 0.06em; color: #5a5a7a; margin-bottom: 6px;
  }

  .two-col { display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin-bottom: 18px; }
  .three-col { display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 14px; margin-bottom: 18px; }

  .panel {
    background: #f8f8fc; border: 1px solid #e8e8f0; border-radius: 8px; padding: 18px;
  }
  .panel.dark { background: #1a1a2e; color: #e0e0f0; border-color: #1a1a2e; }
  .panel.dark h3 { color: #9090bb; }
  .panel.dark strong { color: #fff; }
  .panel.green { border-left: 4px solid #059669; background: #ecfdf5; }

  table { width: 100%; border-collapse: collapse; font-size: 12px; margin-bottom: 14px; }
  table th {
    text-align: left; font-size: 10px; font-weight: 700; text-transform: uppercase;
    letter-spacing: 0.05em; color: #5a5a7a; padding: 7px 10px; border-bottom: 2px solid #1a1a2e;
  }
  table td { padding: 6px 10px; border-bottom: 1px solid #eee; vertical-align: top; }
  table tr:last-child td { border-bottom: none; }
  .mono { font-family: 'JetBrains Mono', monospace; font-size: 11px; }

  .callout {
    background: #1a1a2e; color: #e0e0f0; border-radius: 8px; padding: 16px 20px; margin-bottom: 18px;
  }
  .callout .label {
    font-size: 10px; text-transform: uppercase; letter-spacing: 0.08em; color: #9090bb; margin-bottom: 5px;
  }
  .callout strong { color: #fff; }

  .stat-strip {
    display: grid; grid-template-columns: repeat(4, 1fr); gap: 12px; margin-bottom: 18px;
  }
  .stat-mini {
    text-align: center; padding: 14px 10px;
    background: #f8f8fc; border: 1px solid #e8e8f0; border-radius: 8px;
  }
  .stat-mini .num { font-family: 'DM Serif Display', serif; font-size: 26px; color: #1a1a2e; }
  .stat-mini .lbl { font-size: 10px; color: #5a5a7a; margin-top: 2px; line-height: 1.3; }
  .stat-mini.highlight { background: #1a1a2e; border-color: #1a1a2e; }
  .stat-mini.highlight .num { color: #fff; }
  .stat-mini.highlight .lbl { color: #9090bb; }

  .footer {
    margin-top: 28px; padding-top: 14px; border-top: 1px solid #e0e0e8;
    display: flex; justify-content: space-between; font-size: 10px; color: #8a8aaa;
  }

  /* Bar chart */
  .bar-row { margin-bottom: 8px; }
  .bar-label {
    display: flex; justify-content: space-between; font-size: 11px; font-weight: 600; margin-bottom: 3px;
  }
  .bar-track { height: 26px; background: #eee; border-radius: 4px; overflow: hidden; }
  .bar-fill {
    height: 100%; border-radius: 4px; display: flex; align-items: center;
    padding-left: 10px; font-size: 10px; font-weight: 700; color: #fff;
  }

  /* FX diagram */
  .fx-diagram {
    display: grid; grid-template-columns: 1fr auto 1fr; gap: 16px; align-items: center;
    padding: 20px 24px; background: #f0f7ff; border: 1px solid #bfdbfe;
    border-radius: 8px; margin-bottom: 18px;
  }
  .fx-side { text-align: center; }
  .fx-side .big { font-family: 'DM Serif Display', serif; font-size: 32px; color: #1a1a2e; }
  .fx-side .sub { font-size: 11px; color: #5a5a7a; margin-top: 2px; }
  .fx-arrow { font-size: 24px; color: #1e40af; }

  .caveat {
    font-size: 10px; color: #8a8aaa; font-style: italic; padding: 6px 10px;
    background: #fafafa; border-left: 2px solid #ddd; margin-top: 10px;
  }

  /* Waterfall */
  .waterfall {
    display: flex; align-items: flex-end; gap: 4px; height: 160px;
    margin-bottom: 18px; padding: 10px; background: #f8f8fc;
    border: 1px solid #e8e8f0; border-radius: 8px;
  }
  .wf-bar {
    flex: 1; display: flex; flex-direction: column; justify-content: flex-end;
    align-items: center; height: 100%;
  }
  .wf-amount { font-family: 'JetBrains Mono', monospace; font-size: 10px; font-weight: 700; margin-bottom: 2px; }
  .wf-block { width: 100%; border-radius: 3px; display: flex; align-items: center; justify-content: center; }
  .wf-label { font-size: 9px; color: #5a5a7a; margin-top: 4px; text-align: center; line-height: 1.2; }
</style>
</head>
<body>

<!-- PAGE 1: FX ADVANTAGE + SR&ED -->
<div class="page">

  <div class="header">
    <div>
      <h1>Canadian Advantage Memo</h1>
      <div class="subtitle">FX Arbitrage, SR&ED Credits & Regulatory Head Start</div>
    </div>
    <div class="header-right">
      <div class="company">Umay Care Holdings Inc.</div>
      Data Room — Stage 1B<br>Confidential
    </div>
  </div>

  <div class="callout">
    <div class="label">The Reframe</div>
    US investors often see "Canadian company" as a limitation. The reality is the opposite: Umay's Canadian incorporation creates a <strong>structural 40%+ R&D cost advantage</strong> through FX arbitrage and SR&ED tax credits, a <strong>Health Canada regulatory head start</strong> that de-risks the US pathway, and access to <strong>NRC IRAP co-funding</strong> that reduces the effective burn rate. Being Canadian isn't a compromise — it's a moat.
  </div>

  <!-- HEADLINE NUMBERS -->
  <div class="stat-strip">
    <div class="stat-mini highlight">
      <div class="num">~40%</div>
      <div class="lbl">R&D cost advantage<br>vs. US competitors</div>
    </div>
    <div class="stat-mini">
      <div class="num">$150K</div>
      <div class="lbl">SR&ED credits captured<br>(2023-2024)</div>
    </div>
    <div class="stat-mini">
      <div class="num">30%</div>
      <div class="lbl">Burn rate reduction<br>from SR&ED alone</div>
    </div>
    <div class="stat-mini">
      <div class="num">1.45</div>
      <div class="lbl">CAD/USD exchange rate<br>(approx. current)</div>
    </div>
  </div>

  <!-- FX ADVANTAGE -->
  <span class="badge fx">Section 1 · FX Arbitrage: Earn in USD, Spend in CAD</span>

  <h2>The Currency Math</h2>

  <div class="fx-diagram">
    <div class="fx-side">
      <div class="big">90% USD</div>
      <div class="sub">Revenue (US clinic sales)</div>
    </div>
    <div class="fx-arrow">→ converted at 1.45× →</div>
    <div class="fx-side">
      <div class="big">70% CAD</div>
      <div class="sub">Costs (team, R&D, overhead)</div>
    </div>
  </div>

  <div class="two-col">
    <div class="panel">
      <h3>Revenue Side (US-Denominated)</h3>
      <table>
        <tr><td style="font-weight:600; width:160px;">Current mix</td><td>~90% USD target (US clinic channel)</td></tr>
        <tr><td style="font-weight:600;">Revenue recognition</td><td>USD collected at Shopify checkout</td></tr>
        <tr><td style="font-weight:600;">FX benefit</td><td>Every $1 USD received = ~$1.45 CAD purchasing power</td></tr>
      </table>
    </div>
    <div class="panel">
      <h3>Cost Side (CAD-Denominated)</h3>
      <table>
        <tr><td style="font-weight:600; width:160px;">Team costs</td><td>100% CAD (Edmonton-based)</td></tr>
        <tr><td style="font-weight:600;">R&D / engineering</td><td>~80% CAD (Tangent + internal)</td></tr>
        <tr><td style="font-weight:600;">COGS</td><td>~30% USD (Aztech, components), 70% CAD-equivalent</td></tr>
        <tr><td style="font-weight:600;">Effective split</td><td>~70% CAD / 30% USD costs</td></tr>
      </table>
    </div>
  </div>

  <h2>What This Means in Practice</h2>
  <div class="panel green" style="font-size:12.5px; margin-bottom:18px;">
    <p style="margin-bottom:8px;"><strong>Every $1 USD of investor capital buys approximately $1.40 CAD of engineering and R&D.</strong></p>
    <p style="margin-bottom:8px;">A US-based competitor spending $160K USD on a Product/Tech Lead gets exactly one hire. Umay spends ~$110K USD (= $160K CAD) for the equivalent role — and gets 30% back via SR&ED credits, making the effective cost ~$77K USD.</p>
    <p><strong>Combined: ~40%+ R&D cost advantage per dollar deployed.</strong> This compounds at every headcount addition, every engineering sprint, and every clinical study.</p>
  </div>

  <!-- SR&ED -->
  <span class="badge sred">Section 2 · SR&ED Tax Credits</span>

  <h2>Scientific Research & Experimental Development (SR&ED)</h2>

  <div class="two-col">
    <div>
      <table>
        <tr><td style="font-weight:600; width:160px;">Program</td><td>CRA SR&ED Investment Tax Credit</td></tr>
        <tr><td style="font-weight:600;">Credit rate (CCPC)</td><td>35% refundable on first $3M qualifying expenditures</td></tr>
        <tr><td style="font-weight:600;">Qualifying activities</td><td>Device R&D, firmware development, RestScan CV algorithm work, clinical study design, thermal protocol optimization</td></tr>
        <tr><td style="font-weight:600;">Credits captured</td><td class="mono" style="font-weight:700;">$150K (2023-2024 combined)</td></tr>
        <tr><td style="font-weight:600;">Burn reduction</td><td>~30% of qualifying R&D spend returned as cash</td></tr>
      </table>
    </div>
    <div class="panel dark" style="font-size:12px;">
      <h3>Effective R&D Dollar (Worked Example)</h3>
      <table style="color:#d0d0e8;">
        <tr><td style="color:#fff; font-weight:600; width:200px;">$100K USD deployed to R&D</td><td></td></tr>
        <tr><td>Converted at 1.45 CAD/USD</td><td class="mono" style="color:#fff;">$145,000 CAD</td></tr>
        <tr><td>SR&ED credit (35% of qualifying)</td><td class="mono" style="color:#059669;">– $50,750 CAD returned</td></tr>
        <tr><td style="color:#fff; font-weight:700;">Net cost of $145K CAD R&D</td><td class="mono" style="color:#fff; font-weight:700;">$94,250 CAD</td></tr>
        <tr><td style="color:#fff; font-weight:700;">Effective USD cost</td><td class="mono" style="color:#fff; font-weight:700;">~$65,000 USD</td></tr>
      </table>
      <p style="color:#9090bb; margin-top:8px;">A US competitor needs to spend $145K USD to buy the same R&D output that costs Umay ~$65K USD. That's a <strong style="color:#059669;">55% cost advantage</strong> on qualifying R&D spend.</p>
    </div>
  </div>

  <h2>Additional Canadian Incentive Programs</h2>
  <table>
    <thead><tr><th>Program</th><th>Benefit</th><th>Status</th><th>Annual Value</th></tr></thead>
    <tbody>
      <tr>
        <td style="font-weight:600;">SR&ED (CRA)</td>
        <td>35% refundable tax credit on R&D</td>
        <td style="color:#059669; font-weight:700;">✓ Active — $150K captured</td>
        <td class="mono">$50-100K/yr</td>
      </tr>
      <tr>
        <td style="font-weight:600;">NRC IRAP</td>
        <td>Non-dilutive co-funding for R&D projects</td>
        <td style="color:#059669; font-weight:700;">✓ Active — OARA co-funded</td>
        <td class="mono">Project-based</td>
      </tr>
      <tr>
        <td style="font-weight:600;">Alberta Innovates</td>
        <td>Provincial innovation grants and vouchers</td>
        <td style="color:#d97706; font-weight:700;">◆ Eligible — not yet applied</td>
        <td class="mono">$25-100K</td>
      </tr>
      <tr>
        <td style="font-weight:600;">SIF / CanExport</td>
        <td>Federal market expansion support</td>
        <td style="color:#d97706; font-weight:700;">◆ Eligible for US expansion</td>
        <td class="mono">$50-500K</td>
      </tr>
    </tbody>
  </table>
</div>

<!-- PAGE 2: REGULATORY HEAD START + DUAL ENTITY -->
<div class="page">

  <span class="badge reg">Section 3 · Regulatory Head Start</span>

  <h2>Health Canada Approval as FDA De-Risk</h2>

  <div class="two-col">
    <div class="panel">
      <h3>What Health Canada Approval Means</h3>
      <p style="font-size:12px; margin-bottom:8px;">The Rest device has passed Health Canada's consumer safety assessment under IEC 60335-1. While this is not equivalent to FDA 510(k) clearance, it establishes:</p>
      <p style="font-size:12px; margin-bottom:4px;">→ Electrical safety certified (SGS International)</p>
      <p style="font-size:12px; margin-bottom:4px;">→ EMC/EMF tested (negligible emissions)</p>
      <p style="font-size:12px; margin-bottom:4px;">→ Consumer safety validated (4+ years in market)</p>
      <p style="font-size:12px;">→ Post-market surveillance data (2,996 units, 0.67% return, zero safety incidents)</p>
    </div>
    <div class="panel">
      <h3>How This Accelerates US Pathway</h3>
      <p style="font-size:12px; margin-bottom:8px;">If Umay pursues FDA classification (513(g) or 510(k)), the Health Canada history provides:</p>
      <p style="font-size:12px; margin-bottom:4px;">→ <strong>Established safety record</strong> — 4 years of post-market data</p>
      <p style="font-size:12px; margin-bottom:4px;">→ <strong>Predicate device history</strong> — validated real-world usage</p>
      <p style="font-size:12px; margin-bottom:4px;">→ <strong>Clinical evidence</strong> — N=500 pilot under Canadian institutional sponsor (ISC/SSC)</p>
      <p style="font-size:12px;">→ <strong>Manufacturing quality</strong> — established supply chain with Aztech (also makes Eight Sleep)</p>
    </div>
  </div>

  <h2>Canada DED Market: Fastest-Growing in North America</h2>
  <div class="stat-strip">
    <div class="stat-mini">
      <div class="num">21.3%</div>
      <div class="lbl">Canada DED<br>prevalence</div>
    </div>
    <div class="stat-mini">
      <div class="num">6.3M</div>
      <div class="lbl">Canadians with<br>dry eye disease</div>
    </div>
    <div class="stat-mini highlight">
      <div class="num">9.17%</div>
      <div class="lbl">Canada DED market<br>CAGR (fastest in N.A.)</div>
    </div>
    <div class="stat-mini">
      <div class="num">7.77%</div>
      <div class="lbl">Device segment<br>CAGR</div>
    </div>
  </div>

  <p style="margin-bottom:18px;">Canada's DED market is growing at 9.17% CAGR — the fastest rate in North America. The device segment specifically is projected to grow from $124M to $261M (7.77% CAGR). Umay built its clinic channel in the fastest-growing geography, not the largest. The US expansion extends this into the largest.</p>

  <!-- DUAL ENTITY STRUCTURE -->
  <h2>Dual-Entity Strategy: Canadian HQ + US Sales Subsidiary</h2>
  <div class="two-col">
    <div class="panel">
      <h3>Canadian Entity (Umay Care Holdings Inc.)</h3>
      <table>
        <tr><td style="font-weight:600; width:130px;">Jurisdiction</td><td>Alberta, Canada</td></tr>
        <tr><td style="font-weight:600;">Function</td><td>HQ, R&D, IP ownership, clinical programs, executive team</td></tr>
        <tr><td style="font-weight:600;">Why here</td><td>SR&ED credits, FX advantage, NRC IRAP access, Health Canada relationship, team location</td></tr>
        <tr><td style="font-weight:600;">Status</td><td style="color:#059669; font-weight:700;">✓ Incorporated, operating</td></tr>
      </table>
    </div>
    <div class="panel" style="border: 2px dashed #059669; background:#f8fdf8;">
      <h3>US Subsidiary (Planned)</h3>
      <table>
        <tr><td style="font-weight:600; width:130px;">Jurisdiction</td><td>Delaware C-Corp</td></tr>
        <tr><td style="font-weight:600;">Function</td><td>US sales, 3PL management, 1099 rep agreements, HSA/FSA processing, Shopify US storefront</td></tr>
        <tr><td style="font-weight:600;">Why here</td><td>US investor expectation, clean cap table, US rep contracting, 3PL operations</td></tr>
        <tr><td style="font-weight:600;">Status</td><td style="color:#d97706; font-weight:700;">◆ To be incorporated (pre-US launch)</td></tr>
      </table>
    </div>
  </div>

  <div class="panel green" style="font-size:12px; margin-bottom:16px;">
    <h3>The Best of Both Worlds</h3>
    <p>The dual-entity structure captures the Canadian cost advantage (SR&ED, FX, IRAP) for R&D while presenting a clean US entity for sales, investor relations, and partner contracting. IP remains in the Canadian entity (where it generates SR&ED-eligible expenditure). Revenue flows through the US entity (where the market is). This is the standard structure for Canadian startups selling into the US — used by Shopify, Clearco, Ada, and others at the pre-Series A stage.</p>
  </div>

  <!-- COMPARISON TABLE -->
  <h2>Head-to-Head: Canada-Based vs. US-Based Cost Comparison</h2>
  <table>
    <thead><tr><th>Cost Item</th><th>US Competitor (USD)</th><th>Umay Effective (USD)</th><th>Advantage</th></tr></thead>
    <tbody>
      <tr>
        <td style="font-weight:600;">Product/Tech Lead (annual)</td>
        <td class="mono">$160,000</td>
        <td class="mono" style="color:#059669;">~$77,000</td>
        <td class="mono" style="color:#059669; font-weight:700;">52% savings</td>
      </tr>
      <tr>
        <td style="font-weight:600;">Ops Manager (annual)</td>
        <td class="mono">$100,000</td>
        <td class="mono" style="color:#059669;">~$48,000</td>
        <td class="mono" style="color:#059669; font-weight:700;">52% savings</td>
      </tr>
      <tr>
        <td style="font-weight:600;">$500K R&D spend</td>
        <td class="mono">$500,000</td>
        <td class="mono" style="color:#059669;">~$325,000</td>
        <td class="mono" style="color:#059669; font-weight:700;">35% savings</td>
      </tr>
      <tr>
        <td style="font-weight:600;">Clinical study (N=50)</td>
        <td class="mono">$200,000</td>
        <td class="mono" style="color:#059669;">~$130,000</td>
        <td class="mono" style="color:#059669; font-weight:700;">35% savings</td>
      </tr>
      <tr style="border-top:2px solid #1a1a2e;">
        <td style="font-weight:700;">Representative $2M raise</td>
        <td class="mono" style="font-weight:700;">Buys ~$2M in execution</td>
        <td class="mono" style="font-weight:700; color:#059669;">Buys ~$2.8-3.2M in execution</td>
        <td class="mono" style="font-weight:700; color:#059669;">40-60% more runway</td>
      </tr>
    </tbody>
  </table>

  <div class="callout">
    <div class="label">The One-Liner for Investors</div>
    <p>"A $2M CAD raise into Umay buys 40-60% more execution than the same capital deployed into a US-based competitor. <strong>Canadian costs, US revenue, Canadian tax credits — every dollar works harder.</strong>"</p>
  </div>

  <div class="caveat">FX advantage is subject to currency fluctuation; modeled at 1.45 CAD/USD. SR&ED credit rates assume Canadian-Controlled Private Corporation (CCPC) status and qualifying R&D expenditures. Actual savings depend on the proportion of spend that qualifies. Delaware C-Corp incorporation is a TODO item — required before US rep agreements and US investor conversations.</div>

  <div class="footer">
    <div>Umay Care Holdings Inc. · Edmonton, AB · umay.rest</div>
    <div>Confidential — Data Room Stage 1B · Canadian Advantage Memo</div>
  </div>
</div>

</body>
</html>
